MCKINLEY THOMAS
CIK: 0001041117
MCKINLEY THOMAS's purchase track record
MCKINLEY THOMAS has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2024 | TDOC | $31K | +33.9% | +11.4% | -1.3% |
| 8/6/2024 | TDOC | $82K | +22.2% | +38.9% | +15.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TDOC | ▲ Buy | Option Exercise | 17,467 | — | 5/21/2025 | View on chart |
| TDOC | ▲ Buy | Open Market | 4,000 | $31K | 9/12/2024 | View on chart |
| TDOC | ▲ Buy | Open Market | 4,000 | $29K | 8/7/2024 | View on chart |
| TDOC | ▲ Buy | Open Market | 7,000 | $53K | 8/6/2024 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 9,834 | — | 5/22/2024 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 6,726 | — | 5/24/2023 | View on chart |
| TDOC | ▲ Buy | Option Exercise | 1,638 | — | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Teladoc Launches AI-Powered Remote Monitoring Tools
Teladoc Health has introduced new AI features that turn smartphone cameras into vital sign monitors and add ambient care tools to its Solo platform. These updates aim to strengthen the company's competitive position in digital health. While the stock has recently dipped more than the broader market, analysts maintain an average price target of $7.59, suggesting potential value relative to current levels.
Teladoc Launches AI-Powered Remote Monitoring Tools. Teladoc Health has introduced new AI features that turn smartphone cameras into vital sign monitors and add ambient care tools to its Solo platform. These updates aim to strengthen the company's competitive position in digital health. While the stock has recently dipped more than the broader market, analysts maintain an average price target of $7.59, suggesting potential value relative to current levels.